BDSX News and Press, Biodesix Inc. From 07/12/23

2023-07-12 09:27:52 ET Biodesix ( NASDAQ: BDSX ) jumped ~10% in the pre-market trading Wednesday after announcing that the science journal PLOS ONE published data from its ORACLE study, which returned positive results for the company’s Nodify XL2 Test designed for early d...

New publication in PLOS ONE, a journal of the Public Library of Science, reaffirms clinical utility of the Nodify XL2® proteomic test in a real-world setting Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced to...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that the Centers for Medicare & Medicaid Services (CMS) has designated the Nodify CDT ® Test as an Advanced Diagnostic Laboratory Test (ADLT) effective June...

5,000 patients with non-small cell lung cancer enrolled to be monitored up to three years Biodesix, Inc . (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the large multi-center observational registry study INSIGHT...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Fri...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at William Blair’s 43rd Annual Growth Stock Confer...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health ...

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at th...

2023-05-14 11:53:04 ET Biodesix, Inc. (BDSX) Q1 2023 Earnings Conference Call May 11, 2023 04.30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Cal...

2023-05-11 16:20:49 ET Biodesix press release ( NASDAQ: BDSX ): Q1 GAAP EPS of -$0.24 in-line. Revenue of $9.05M (+38.2% Y/Y) beats by $0.35M . For further details see: Biodesix GAAP EPS of -$0.24 in-line, revenue of $9.05M beats by $0.35M